Technology area: Biotechnology & Pharmaceuticals
16 pending office actions • 14 art units • 16 examiners • 0 of 16 (0%) have an AI response strategy ready • 14 patents granted in the last 365 days
Celgene Corporation has 17 pending office actions in Biotechnology & Pharmaceuticals. The matters span 17 distinct examiners and 15 distinct art units. TCHERKASSKAYA, OLGA V is the busiest examiner, with 1 pending matter, so the reported docket is broadly distributed.
The examiner count requires rigorous application-level tracking, while the art-unit assignments show limited technical overlap in the overall record. Counsel should use centralized portfolio controls for deadlines, disclosures, and terminology, but avoid assuming that arguments will transfer unchanged between art units. Examiner-specific claim construction and prior-art analysis should remain central to each response.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (6%) |
| §103 only | 2 (12%) |
| §112 only | 3 (19%) |
| Double-patenting only | 3 (19%) |
| Double-patenting + other | 5 (31%) |
| Multi-statute (no §101) | 2 (12%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TCHERKASSKAYA, OLGA V | 1 | 55.5% | +46.4% |
| DAVIS, BRIAN J | 1 | 84.8% | -3.9% |
| BAEK, BONG-SOOK | 1 | 41.6% | +69.9% |
| WARD, PAUL V | 1 | 83.2% | -12.2% |
| CORNET, JEAN P | 1 | 41.9% | +47.2% |
| WILSON, MICHAEL C | 1 | 41.5% | +17.8% |
| BARSKY, JARED | 1 | 50.3% | +22.8% |
| PUTTLITZ, KARL J | 1 | 69.2% | +18.5% |
| RAHMANI, NILOOFAR | 1 | 77.6% | -2.9% |
| BELL, SARA ELIZABETH | 1 | 68.8% | +38.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18776606 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | DAVIS, BRIAN J | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18767295 | PHARMACEUTICAL COMPOSITIONS COMPRISING (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-FLUOROBENZONITRILE AND METHODS OF USING THE SAME | BAEK, BONG-SOOK | — |
| 18763757 | METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO THERAPIES | WARD, PAUL V | — |
| 18546155 | Methods for Treating Multiple Myeloma | BENAVIDES, JENNIFER ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18800988 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | TCHERKASSKAYA, OLGA V | — |
| 18767295 | PHARMACEUTICAL COMPOSITIONS COMPRISING (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-FLUOROBENZONITRILE AND METHODS OF USING THE SAME | BAEK, BONG-SOOK | — |
| 18714760 | Carboxylic Acid Containing Indanyl Compounds for the Treatment of Neurodegenerative Diseases | CORNET, JEAN P | — |
| 18609867 | TRANSGENIC MOUSE EXPRESSING HUMAN CEREBLON | WILSON, MICHAEL C | — |
| 18682370 | PROCESS FOR PREPARING HISTONE DEMETHYLASE INHIBITORS | BARSKY, JARED | — |
| 18427510 | COMBINATION THERAPIES USING AN ANTI-BCMA ANTIBODY DRUG CONJUGATE (ADC) IN COMBINATION WITH A GAMMA SECRETASE INHIBITOR (GSI) | PUTTLITZ, KARL J | — |
| 18573790 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BELL, SARA ELIZABETH | — |
| Art Unit | Apps |
|---|---|
| 1628 | 2 |
| 1675 | 2 |
| 1615 | 1 |
| 1614 | 1 |
| 1611 | 1 |
| 1622 | 1 |
| 1638 | 1 |
| 1642 | 1 |
| 1691 | 1 |
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18800988 | ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF | TCHERKASSKAYA, OLGA V | 1615 | §112DP | Non-Final OA | — | Pending | Aug 12, 2024 |
| 18776606 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | DAVIS, BRIAN J | 1614 | §112DP | Non-Final OA | — | Pending | Jul 18, 2024 |
| 18767295 | PHARMACEUTICAL COMPOSITIONS COMPRISING (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-FLUOROBENZONITRILE AND METHODS OF USING THE SAME | BAEK, BONG-SOOK | 1611 | §102§103Other | Non-Final OA | — | Pending | Jul 09, 2024 |
| 18763757 | METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS AND THE USE OF BIOMARKERS AS A PREDICTOR OF CLINICAL SENSITIVITY TO THERAPIES | WARD, PAUL V | 1622 | §103§112 | Non-Final OA | — | Pending | Jul 03, 2024 |
| 18714760 | Carboxylic Acid Containing Indanyl Compounds for the Treatment of Neurodegenerative Diseases | CORNET, JEAN P | 1628 | §103 | Non-Final OA | — | Pending | May 30, 2024 |
| 18609867 | TRANSGENIC MOUSE EXPRESSING HUMAN CEREBLON | WILSON, MICHAEL C | 1638 | §112 | Non-Final OA | — | Pending | Mar 19, 2024 |
| 18682370 | PROCESS FOR PREPARING HISTONE DEMETHYLASE INHIBITORS | BARSKY, JARED | 1628 | §112 | Non-Final OA | — | Pending | Feb 08, 2024 |
| 18427510 | COMBINATION THERAPIES USING AN ANTI-BCMA ANTIBODY DRUG CONJUGATE (ADC) IN COMBINATION WITH A GAMMA SECRETASE INHIBITOR (GSI) | PUTTLITZ, KARL J | 1642 | DP | Non-Final OA | — | Pending | Jan 30, 2024 |
| 18419894 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | RAHMANI, NILOOFAR | 1691 | DP | Final Rejection | 14d | Pending | Jan 23, 2024 |
| 18573790 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BELL, SARA ELIZABETH | 1625 | §112 | Non-Final OA | — | Pending | Dec 22, 2023 |
| 18563037 | METHODS OF TREATING MULTIPLE MYELOMA USING COMBINATION THERAPY | METCALF, MATTHEW CURRAN | 1647 | §103DP | Non-Final OA | — | Pending | Nov 21, 2023 |
| 18546155 | Methods for Treating Multiple Myeloma | BENAVIDES, JENNIFER ANN | 1675 | §101§103 | Non-Final OA | — | Pending | Aug 11, 2023 |
| 18012414 | METHODS FOR TREATING CANCER WITH COMBINATION THERAPIES | TOWNSLEY, SARA ELIZABETH | 1629 | §103Other | Non-Final OA | — | Pending | Aug 08, 2023 |
| 17995915 | METHODS FOR TREATING ANEMIA USING AN ACTRIIB LIGAND TRAP AND FEDRATINIB | BORGEEST, CHRISTINA M | 1675 | §103DP | Non-Final OA | — | Pending | Oct 10, 2022 |
| 17867294 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | NESTOR, DONNA MICHELLE | 1627 | DP | Non-Final OA | 73d overdue | Pending | Jul 18, 2022 |
| 17620541 | AZACITIDINE IN COMBINATION WITH VENETOCLAX, GILTERITINIB, MIDOSTAURIN OR OTHER COMPOUNDS FOR TREATING LEUKEMIA OR MYELODYSPLASTIC SYNDROME | BERRY, LAYLA D | 1693 | §103DP | Non-Final OA | 48d | Pending | Dec 17, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCelgene Corporation has 16 pending office actions as of October 2026, spread across 14 art units and 16 examiners.
Olga V Tcherkasskaya has the most, with 1 of Celgene Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
